<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tricuspid stenosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tricuspid stenosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tricuspid stenosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ferande Peters, MBBCH FCP(SA) FESC FACC FRCP (London)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine M Otto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tricuspid stenosis (TS) is an uncommon valvular abnormality that is usually found in combination with tricuspid regurgitation and other valvular lesions. TS is rarely an isolated valve lesion.</p><p>The clinical features of TS and the management of patients with this lesion will be reviewed here.</p><p>The diagnosis and management of tricuspid regurgitation is discussed separately. (See  <a class="medical medical_review" href="/d/html/8119.html" rel="external">"Etiology, clinical features, and evaluation of tricuspid regurgitation"</a> and  <a class="medical medical_review" href="/d/html/8145.html" rel="external">"Management and prognosis of tricuspid regurgitation"</a>.)</p><p>Diagnosis and management of tricuspid prosthetic valve obstruction are discussed separately. (See  <a class="medical medical_review" href="/d/html/113815.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/111633.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Management"</a> and  <a class="medical medical_review" href="/d/html/8121.html" rel="external">"Mechanical prosthetic valve thrombosis or obstruction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/113809.html" rel="external">"Management of mechanical prosthetic valve thrombosis and obstruction"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Causes of native TS include the following conditions [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acquired causes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rheumatic heart disease is the most common cause of TS. Most cases of tricuspid rheumatic disease present with tricuspid regurgitation or a combination of regurgitation and stenosis; pure TS is very uncommon [<a href="#rid3">3,4</a>]. Rheumatic tricuspid disease almost never occurs as an isolated lesion but is nearly always associated with mitral valve disease and, in some cases, aortic valve disease [<a href="#rid5">5,6</a>]. In an angiographic study of 525 patients with rheumatic heart disease, 9 percent had TS, and all patients with TS also had significant tricuspid regurgitation [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carcinoid syndrome is a cause of TS [<a href="#rid8">8</a>], although tricuspid regurgitation is more common and is generally predominant when combined with TS. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benign or malignant tumors in the right heart can obstruct flow through the tricuspid valve and thus cause functional TS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypereosinophilic syndromes rarely cause TS [<a href="#rid9">9</a>]. Hypereosinophilia has been linked to endomyocardial fibrosis which is commonly associated with mitral or tricuspid regurgitation and rarely associated with TS [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/4927.html" rel="external">"Endomyocardial fibrosis"</a> and  <a class="medical medical_review" href="/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infective endocarditis rarely causes isolated TS but may cause mixed tricuspid disease (tricuspid regurgitation and TS), particularly when large vegetations are present [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/2149.html" rel="external">"Right-sided native valve infective endocarditis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonbacterial thrombotic endocarditis (NBTE, also known as Libman-Sacks endocarditis or marantic endocarditis) is a form of noninfectious endocarditis with sterile platelet thrombi deposition on heart valves (predominantly aortic and mitral, with the tricuspid valve less commonly involved [<a href="#rid12">12</a>]). NBTE is associated with a number of conditions including advanced malignancy, systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, sepsis, and burns. (See  <a class="medical medical_review" href="/d/html/91781.html" rel="external">"Nonbacterial thrombotic endocarditis"</a> and  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fabry disease is commonly associated with mitral, tricuspid, or aortic regurgitation; it is rarely associated with TS [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/4914.html" rel="external">"Fabry disease: Cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Light chain amyloid deposition has been documented to cause concomitant moderately severe tricuspid and mitral valve stenosis [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Iatrogenic causes:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Injury of the tricuspid valve apparatus associated with endocardial pacemaker lead(s) or endomyocardial biopsy procedures (with [<a href="#rid15">15-18</a>] or without [<a href="#rid19">19,20</a>] associated infection [<a href="#rid21">21</a>]). Rarely, large tricuspid vegetations may cause stenosis. Pacemaker lead looping may also interfere with valve opening. (See  <a class="medical medical_review" href="/d/html/2146.html" rel="external">"Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Radiation therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ergotamine therapy. This is a rare cause of TS [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/8125.html" rel="external">"Valvular heart disease induced by drugs", section on 'Ergot derivatives'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A malaligned ventricular septal occluder device. This is a rare cause of TS with tricuspid regurgitation [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital causes include congenital tricuspid valve atresia or stenosis of the valve including an atypical presentation of Ebstein anomaly [<a href="#rid24">24,25</a>] (which is usually associated with tricuspid regurgitation rather than TS). (See  <a class="medical medical_review" href="/d/html/14587.html" rel="external">"Tricuspid valve atresia"</a> and  <a class="medical medical_review" href="/d/html/8146.html" rel="external">"Ebstein anomaly: Clinical manifestations and diagnosis"</a>.)</p><p></p><p>Prosthetic tricuspid valve stenosis is an increasingly common lesion and may occur with [<a href="#rid26">26</a>] or without associated endocarditis [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/d/html/113815.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>As a result of tricuspid valvular stenosis, there is a persistent diastolic pressure gradient between the right atrium and right ventricle. This gradient increases when blood flow across the tricuspid valve increases, as occurs with inspiration and exercise, and decreases when blood flow decreases, such as with expiration. (See  <a class="medical medical_review" href="/d/html/8127.html" rel="external">"Hemodynamics of valvular disorders as measured by cardiac catheterization"</a>.)</p><p>As a result, most patients with significant TS have elevated right atrial pressures and display clinical features suggestive of systemic venous congestion, such as jugular venous distension, ascites, and peripheral edema. (See  <a class="medical medical_review" href="/d/html/1515.html" rel="external">"Cardiac catheterization techniques: Normal hemodynamics"</a> and  <a class="medical medical_review" href="/d/html/1076.html" rel="external">"Examination of the jugular venous pulse"</a>.)</p><p>During sinus rhythm, the right atrial a-wave is increased and may approach the level of right ventricular systolic pressure. When severe TS is present, the resting cardiac output may be reduced and fails to increase with exercise. In patients with significant mitral valve disease and significant TS, the left atrial and pulmonary pressures may be only modestly elevated due to proximal coexisting severe TS.</p><p>Reverse Lutembacher syndrome is a rare cause of hypoxia characterized by the triad of TS, elevated right atrial pressure, and an interatrial right-to-left shunt [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1759080270"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical features of isolated TS arise from a combination of obstruction to tricuspid flow, which limits cardiac output and may cause fatigue, and elevated right atrial pressure, which produces symptoms and signs of systemic venous hypertension. When TS is not an isolated lesion, the clinical features of systemic congestion are usually detected, but the associated clinical features of coexisting TR or left-sided valve lesions may be more prominent, and, consequently, TS is often not suspected. (See  <a class="medical medical_review" href="/d/html/13612.html" rel="external">"Clinical manifestations and diagnosis of rheumatic heart disease", section on 'Chronic valve disease'</a> and  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H1759080276"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>In the absence of mitral or aortic valve disease, symptoms and signs of systemic venous hypertension are generally out of proportion to dyspnea. However, most patients with TS (particularly those with rheumatic heart disease) have significant mitral and/or aortic valve disease [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/13612.html" rel="external">"Clinical manifestations and diagnosis of rheumatic heart disease"</a>.)</p><p>Patients with TS often complain of abdominal discomfort, which is due to the presence of hepatomegaly secondary to hepatic congestion. Fatigue and effort intolerance may be caused by diminished cardiac output. Some patients may sense a fluttering discomfort in the neck, caused by tall a-waves in the jugular venous pulse. (See <a class="local">'Physical examination'</a> below.)</p><p class="headingAnchor" id="H1759080282"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical findings include jugular venous distension, hepatomegaly and hepatic pulsations, ascites, peripheral edema, and, occasionally, anasarca. The findings seen on physical examination in patients with TS are similar to those of mitral stenosis. Since these two lesions often coexist, the diagnosis of TS may be missed.</p><p>Obstruction to flow across the tricuspid valve produces an increase in right atrial and jugular venous pressure. Jugular venous pulsations often exhibit a prominent presystolic a-wave, which may be confused with an arterial pulsation. The specificity of a prominent a-wave is reduced when coexisting pulmonary hypertension is present. The y-descent is slow and barely appreciated. Kussmaul sign (lack of decrease or a rise in jugular venous pressure with inspiration) may be seen. A jugular or clavicular presystolic click may be heard [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/1076.html" rel="external">"Examination of the jugular venous pulse"</a>.)</p><p>The lungs are clear in patients with isolated TS. Signs of pulmonary congestion are present in some patients with concurrent mitral valve disease. (See  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation", section on 'Physical examination'</a> and  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis", section on 'Physical examination'</a>.)</p><p>On auscultation, an opening snap of the tricuspid valve has been described but, when mitral stenosis is also present, it would be difficult to distinguish from the opening snap of mitral stenosis. The tricuspid opening snap usually follows the opening snap of the mitral valve and is localized to the lower left sternal border. (See  <a class="medical medical_review" href="/d/html/1079.html" rel="external">"Auscultation of heart sounds", section on 'Tricuspid valve'</a>.)</p><p>A low frequency diastolic murmur is heard at the lower left sternal border in the fourth intercostal space; it is usually softer, higher pitched, and shorter in duration than the murmur of mitral stenosis. The intensity of the murmur and opening snap in TS increases with maneuvers that increase blood flow across the tricuspid valve, especially with inspiration (Carvallo sign), and also with leg raising, inhalation of amyl nitrate, squatting, or exercise. A middiastolic murmur in the tricuspid valve area may also occur in the absence of TS in patients with a large atrial septal defect, but an opening snap will not be present. (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults", section on 'Tricuspid stenosis'</a> and  <a class="medical medical_review" href="/d/html/1080.html" rel="external">"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds"</a>.)</p><p class="headingAnchor" id="H1776775818"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Liver biochemical test abnormalities, including mild elevation in the serum bilirubin (most of which is unconjugated), occur in patients with hepatic congestion. Other liver biochemical tests, such as serum alkaline phosphatase and serum aminotransferase levels, may be normal or mildly increased. Serum albumin levels may be normal or mildly depressed. (See  <a class="medical medical_review" href="/d/html/3592.html" rel="external">"Congestive hepatopathy"</a>.)</p><p class="headingAnchor" id="H1942933783"><span class="h2">Chest radiograph</span><span class="headingEndMark"> — </span>A chest radiograph is not indicated to diagnose TS but may be obtained in patients with dyspnea caused by concomitant valve disease (eg, mitral stenosis). The nonspecific finding of right atrial enlargement is seen with TS. In patients with concomitant mitral valve disease, additional findings may be seen, such as evidence of pulmonary edema (including redistribution of pulmonary blood flow to the upper lobes, and interstitial edema), left atrial enlargement, or a straight left heart border. (See  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis", section on 'Chest radiograph'</a>.)</p><p>In patients with TS caused by endocardial pacemaker lead(s), looped atrial or ventricular leads are commonly (but not always) seen on the chest radiograph [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H2007697841"><span class="h2">Electrocardiogram</span><span class="headingEndMark"> — </span>An electrocardiogram is not indicated to diagnose TS but is commonly obtained in the evaluation of patients with valvular heart disease to identify concurrent conditions such as atrial fibrillation (which occurs frequently in patients with rheumatic heart disease) and as a baseline for future comparison. In patients with TS in sinus rhythm, the electrocardiogram may show tall, peaked P waves in leads II, III, and avF consistent with right atrial enlargement [<a href="#rid31">31</a>]. Most patients with rheumatic heart disease have concurrent mitral disease, with associated electrocardiographic changes, including signs of left atrial enlargement and atrial fibrillation. (See  <a class="medical medical_review" href="/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis", section on 'Electrocardiogram'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSIS AND EVALUATION</span></p><p class="headingAnchor" id="H1759080347"><span class="h2">Approach to diagnosis and evaluation</span><span class="headingEndMark"> — </span>TS should be suspected in patients with signs and symptoms of systemic venous hypertension, particularly those with conditions associated with TS. TS related to pacemaker leads should be suspected in patients with chronic endocardial leads presenting with right heart failure. (See <a class="local">'Etiology'</a> above.)</p><p>TS is generally diagnosed and evaluated by transthoracic echocardiogram, which is often performed to evaluate other associated suspected valve lesions.</p><p>Cardiac catheterization for hemodynamic assessment of the severity of TS is generally not required but is suggested in symptomatic patients when clinical and noninvasive data are discordant. When patients with left-sided valve disease and pulmonary hypertension undergo catheterization, an assessment for TS should be performed.</p><p class="headingAnchor" id="H8"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>The diagnosis of TS is generally based upon identifying the following combination of echocardiographic abnormalities [<a href="#rid32">32</a>]. The following echocardiographic features are seen with TS:</p><p class="bulletIndent1"><span class="glyph">●</span>Tricuspid valve leaflets are thickened and distorted with limited leaflet mobility, reduced separation of the leaflet tips, and diastolic doming of the valve. The degree of thickening and calcification with rheumatic TS is generally less pronounced than that seen in rheumatic mitral stenosis. (See  <a class="medical medical_review" href="/d/html/5292.html" rel="external">"Echocardiographic evaluation of the tricuspid valve", section on 'Tricuspid stenosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Doppler echocardiography reveals high velocity turbulent diastolic flow across the stenotic orifice and prolonged pressure half-time (T<sub>1/2</sub>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With severe TS, the pressure half-time is ≥190 ms and the valve area is ≤1 cm<sup>2</sup>. The tricuspid valve area in cm<sup>2</sup><sub> </sub>may be estimated by dividing 190 by the pressure half-time [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With severe TS, the gradient across the tricuspid valve is variable, as it is affected by heart rate, forward flow, and respiratory phase.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>With preserved cardiac output and a heart rate of 70 bpm, the mean pressure gradient is usually 5 to 10 mmHg. Higher gradients may occur with combined TS and tricuspid regurgitation [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>With a low output state (such as with concomitant severe mitral stenosis), severe TS is associated with lower tricuspid valve gradients. When the gradient is low, other echocardiographic features may suggest severe TS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The hemodynamic effects of TS cause dilation of the right atrium and inferior vena cava. (See  <a class="medical medical_review" href="/d/html/5326.html" rel="external">"Echocardiographic evaluation of the atria and appendages", section on 'Right atrium'</a> and  <a class="medical medical_review" href="/d/html/83974.html" rel="external">"Echocardiographic assessment of the right heart", section on 'RA pressure'</a>.)</p><p></p><p>Echocardiographic findings may also help establish the etiology of TS. For example, presence of pacemaker leads, particularly looped leads, suggests pacemaker lead-related TS.</p><p>It is also important to assess the presence and severity of concomitant tricuspid regurgitation since this can influence the decision to proceed with tricuspid valve surgery or balloon valvotomy. In patients with concomitant tricuspid regurgitation, the higher flow through the tricuspid valve further increases the gradient across the valve and the elevation of right atrial pressures [<a href="#rid7">7</a>]. (See <a class="local">'Indications for intervention'</a> below and  <a class="medical medical_review" href="/d/html/5292.html" rel="external">"Echocardiographic evaluation of the tricuspid valve"</a>.)</p><p>The presence of concomitant valve disease should also be assessed, particularly in patients with rheumatic heart disease who commonly have mitral valve disease and sometimes also aortic valve disease.</p><p>Three-dimensional transesophageal echocardiography provides better qualitative data on the morphological abnormalities seen on two-dimensional echo as it allows for en face visualization of the valve, and planimetry of the valve area can be performed. However, the utility of three-dimensional transesophageal echo for assessment of TS has not been systematically studied.</p><p class="headingAnchor" id="H9"><span class="h2">Cardiac catheterization</span><span class="headingEndMark"> — </span>Right heart catheterization is performed with two catheters or one double lumen catheter. After calibration of the two transducers, it is important first to document identical simultaneous recordings of right atrial pressure and then to advance one of the catheters into the right ventricular cavity. Simultaneous recordings of atrial and ventricular pressure are made in at least 8 to 10 cardiac cycles.</p><p>As noted above, at a heart rate of 70 bpm, the mean pressure gradient in severe TS is usually 5 to 10 mmHg. Diastolic pressure gradients as low as 2 to 4 mmHg may indicate severe TS; gradients rarely exceed 10 mmHg. Thus, respiratory variation of a relatively low pressure gradient or non-simultaneous measurements may provide misleading data. A single catheter "pull-back" from the ventricle to the atrium does <strong>NOT</strong> provide a sufficiently accurate measurement of the pressure gradient. (See  <a class="medical medical_review" href="/d/html/8127.html" rel="external">"Hemodynamics of valvular disorders as measured by cardiac catheterization"</a>.)</p><p>Cardiac output is measured using the Fick principle, and the valve area is calculated in a manner similar to that used to calculate the mitral valve area. A tricuspid valve area less than 1 cm<sup>2</sup> indicates severe TS [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/8127.html" rel="external">"Hemodynamics of valvular disorders as measured by cardiac catheterization", section on 'Tricuspid stenosis'</a>.)</p><p class="headingAnchor" id="H89926186"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of TS includes other causes of systemic venous hypertension and right heart failure, such as tricuspid regurgitation, right ventricular dysfunction, constrictive pericarditis, and restrictive cardiomyopathy [<a href="#rid36">36</a>]. The conditions are generally distinguished from TS by echocardiography.</p><p>TS has characteristic tricuspid valve morphological abnormalities and Doppler findings. These tricuspid abnormalities occur in the absence of ventricular dysfunction, other valve disease, or pericardial disease. (See  <a class="medical medical_review" href="/d/html/1080.html" rel="external">"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds"</a>.)</p><p class="headingAnchor" id="H1759080570"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Severe TS is identified by valve anatomy, valve hemodynamics, and hemodynamic consequences largely based upon echocardiographic findings as described above [<a href="#rid32">32</a>]. Symptoms of severe TS vary from none to severe, depending upon degree of obstruction and coexisting valve disease. (See <a class="local">'Echocardiography'</a> above and  <a class="medical medical_review" href="/d/html/5292.html" rel="external">"Echocardiographic evaluation of the tricuspid valve", section on 'Tricuspid stenosis'</a>.)</p><p>No criteria for Stages A or B were included in the 2014 American Heart Association/American College of Cardiology valve guidelines [<a href="#rid32">32</a>]. Stage C is defined as severe TS without symptoms. Stage D is defined as severe TS with symptoms.</p><p class="headingAnchor" id="H2007698410"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2007699192"><span class="h2">Approach to treatment</span><span class="headingEndMark"> — </span>Limited data are available to guide treatment of TS. Since TS is a mechanical disorder, it is most effectively treated by valve intervention with either valve surgery (valve repair or replacement) or percutaneous balloon valvotomy. Medical management with diuretic therapy may help reduce symptoms of congestion and thus may be helpful prior to intervention as well as in patients who are not candidates for intervention.</p><p>Thus, treatment of many patients with TS involves a combination of medical therapy and valve intervention. As an example, treatment of symptomatic severe TS related to pacemaker leads generally includes removal of the involved endocardial lead(s) (which may be replaced by an epicardial system for patients who continue to require a pacemaker), tricuspid valve surgery, and treatment of any associated infection. Case reports have described percutaneous valvotomy as a potential alternative to surgery in selected patients with lead-associated TS [<a href="#rid37">37-39</a>].</p><p class="headingAnchor" id="H1759080609"><span class="h2">Medical management</span><span class="headingEndMark"> — </span>In patients with severe TS, symptoms of systemic venous hypertension, including lower extremity edema and hepatic congestion, are treated with loop diuretics [<a href="#rid32">32,40</a>]. However, diuretic therapy has limited efficacy in patients with TS and use may be limited by worsening low-flow syndrome. (See  <a class="medical medical_review" href="/d/html/127128.html" rel="external">"Right heart failure: Causes and management", section on 'Management'</a>.)</p><p>Specific therapy is indicated for treatment of some of the causes of TS, such as systemic rheumatic diseases and endocarditis. In some instances, treatment of the underlying etiology (systemic lupus erythematosus and antiphospholipid syndrome) may reduce the degree of stenosis [<a href="#rid41">41</a>]. Reversal of tricuspid valve abnormality has also been documented with the cessation of <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> or methysergide use [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/8139.html" rel="external">"Rheumatic mitral stenosis: Overview of management"</a> and <a class="local">'Etiology'</a> above and  <a class="medical medical_review" href="/d/html/8125.html" rel="external">"Valvular heart disease induced by drugs"</a>.)</p><p>Medical therapy is also indicated for associated conditions such as atrial fibrillation. (See  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.)</p><p>Data on outcomes of medical management of TS are limited, and controlled data are lacking. A retrospective series indicated that some patients with significant TS and systemic venous hypertension have prolonged survival [<a href="#rid5">5</a>], but limited information is available on the risk of morbidity and mortality in such patients. Of 13 patients with severe TS included in the study, 12 underwent mitral and/or aortic valve surgery; six underwent concomitant tricuspid valve repair and six underwent no intervention. At 6- to 31-year follow-up, 9 of the 13 patients were in New York Heart Association functional class I or II; the medical treatment received by these nine patients was not specified.</p><p class="headingAnchor" id="H1770084248"><span class="h2">Intervention</span></p><p class="headingAnchor" id="H10"><span class="h3">Indications for intervention</span><span class="headingEndMark"> — </span>Tricuspid valve intervention for TS (ie, valve surgery [valve repair or replacement] or percutaneous balloon valvotomy) is generally reserved for symptomatic patients with severe TS. Among patients with symptomatic severe TS who are candidates for intervention, a choice is made between valve surgery and balloon valvotomy based upon considerations including surgical risk, the presence of tricuspid regurgitation and risk of worsening regurgitation with valvotomy, and operator experience.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with isolated symptomatic severe TS with low to moderate surgical risk, we suggest tricuspid valve surgery rather than balloon valvotomy. Tricuspid valve surgery (valve repair or replacement) is generally preferred over percutaneous balloon tricuspid valvotomy in this setting since there is greater experience with surgery, most cases of severe TS are accompanied by tricuspid regurgitation, and balloon valvotomy may create or worsen tricuspid regurgitation [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with isolated symptomatic severe TS and mild or less tricuspid regurgitation with high surgical risk, we suggest balloon valvotomy. Tumor masses, vegetations, and thrombi are contraindications to valvotomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with isolated symptomatic severe TS and moderate or greater tricuspid regurgitation with high surgical risk, we perform an individualized assessment of the risks and benefits of tricuspid valve surgery versus medical therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe TS requiring surgery for left-sided valve disease, we suggest concomitant tricuspid valve surgery.</p><p></p><p>Similar recommendations are included in the 2014 with 2017 update American Heart Association/American College of Cardiology (AHA/ACC) valve guideline and in the 2017 European Society of Cardiology (ESC) valve guidelines [<a href="#rid32">32,43,44</a>].</p><p>Limited evidence is available to guide management of TS, so recommendations for treatment of TS are largely based upon expert opinion and limited observational data. Few data are available on outcomes in patients with TS with medical management intervention (tricuspid valve surgery or percutaneous valvotomy). Studies comparing percutaneous balloon valvotomy with tricuspid valve surgery are not available. Reports of tricuspid balloon valvotomy are scant [<a href="#rid45">45,46</a>] and lack long-term follow-up. Larger studies reporting surgical outcomes for tricuspid valve surgery did not separate cases with predominant TS from those with predominant tricuspid regurgitation [<a href="#rid47">47,48</a>]. (See <a class="local">'For valve surgery'</a> below.)</p><p>Management of tricuspid prosthetic valve obstruction is discussed separately. (See  <a class="medical medical_review" href="/d/html/113815.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/111633.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Management"</a> and  <a class="medical medical_review" href="/d/html/8121.html" rel="external">"Mechanical prosthetic valve thrombosis or obstruction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/113809.html" rel="external">"Management of mechanical prosthetic valve thrombosis and obstruction"</a>.) </p><p class="headingAnchor" id="H334503395"><span class="h3">Outcomes and complications</span><span class="headingEndMark"> — </span>Outcomes following intervention in patients with severe TS have not been well defined. Isolated TS is uncommon, so most patients undergoing intervention for TS undergo concomitant intervention for concurrent mitral and/or aortic disease.</p><p class="headingAnchor" id="H3635582074"><span class="h4">For valve surgery</span><span class="headingEndMark"> — </span>Limited data are available on efficacy and outcomes of tricuspid valve surgery for patients with TS. In surgical series, patients with predominant TS are often combined with those with predominant tricuspid regurgitation or mixed stenosis and regurgitation and other types of valve disease [<a href="#rid21">21,32,47,48</a>].</p><p>Complications following tricuspid valve surgery are the same as those for other valve surgery, including mortality, prolonged ventilation, renal failure, pneumonia, sepsis, neurologic complications, bleeding, and multiorgan failure. The atrioventricular node may be injured when suturing in the region of the anteroseptal commissure encroaches upon myocardial tissue at the atrioventricular node [<a href="#rid21">21</a>]. A minority of patients undergoing tricuspid valve surgery develop atrioventricular block, requiring permanent pacemaker placement. The rate of pacemaker placement is higher following tricuspid valve replacement than following tricuspid valve repair (eg, 17.2 versus 9.5 percent) [<a href="#rid48">48</a>]. Iatrogenic stenosis of the right coronary artery has been reported and may be caused by tension on adjacent tissues causing functional stenosis or by direct suturing of the artery [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/1627.html" rel="external">"Postoperative complications among patients undergoing cardiac surgery"</a>.)</p><p>Operative mortality for tricuspid valve surgery is approximately 10 percent. A Society of Thoracic Surgeons (STS) database study reported an operative mortality for tricuspid valve surgery (repair or replacement) of 10 percent, which remained similar from 1993 to 1997 and 2003 to 2007 [<a href="#rid47">47</a>]. Similarly, a study of isolated valve surgery outcomes using the Nationwide Inpatient Sample (NIS) database from 1999 to 2008 reported an overall hospital mortality of 10.6 percent [<a href="#rid48">48</a>]. The presence of liver disease was a risk factor for mortality.</p><p>Most tricuspid valve surgery (eg, 80 percent [<a href="#rid48">48</a>]) is performed as a concomitant procedure with other cardiac surgery, and surgery involving more than one valve is generally associated with an increased risk compared with isolated tricuspid valve surgery. In the NIS database study, hospital mortality for tricuspid surgery plus other cardiac surgery was 16.1 percent (significantly higher than for tricuspid surgery alone at 10.6 percent) [<a href="#rid48">48</a>]. In the STS database study, operative mortality for mitral plus tricuspid valve surgery was 8.7 percent during 2003 to 2007, operative mortality for aortic plus tricuspid valve surgery was 11.8 percent during 2003 to 2007, and operative mortality for combined aortic, mitral, and tricuspid valve surgery was 13.1 percent [<a href="#rid47">47</a>].</p><p>Few studies have reported long-term survival after tricuspid valve replacement (for tricuspid regurgitation or TS) and data for controls are generally not available:</p><p class="bulletIndent1"><span class="glyph">●</span>A review reported survival rates for hospital-discharged patients with tricuspid valve prostheses with mean age 49.3 at implantation [<a href="#rid49">49</a>]. Survival rates at 1, 5, 10, and 15 years were 86.9, 73.5, 60.2, and 47.8 percent for patients with mechanical tricuspid prostheses and 86.7, 73.6, 62.0, and 46.7 percent for patients with bioprosthetic tricuspid valves.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term follow-up was reported for 530 patients undergoing cardiac surgery that included a tricuspid valve procedure (66 percent repair and 34 percent replacement) at a mean age of 56.9 years. Of the patients undergoing tricuspid valve replacement, 86.6 percent received a bioprosthetic valve. Actuarial survival rate was 20 percent at 15 years.</p><p></p><p class="headingAnchor" id="H1145088412"><span class="h4">For balloon valvotomy</span><span class="headingEndMark"> — </span>Data on outcomes following balloon valvotomy for TS are limited. There is far less experience with tricuspid valvotomy than with mitral valvotomy. Valve areas generally increase from less than 1 to almost 2 cm<sup>2</sup> [<a href="#rid50">50</a>]. While some stenosis persists, this change in area is sufficient to produce a significant reduction in the transvalvular pressure gradient and a decrease in right atrial pressure. Successful valvotomy using one, two, or three balloons has been described [<a href="#rid51">51-53</a>]. Similar beneficial results have been described when balloon valvotomy is used to treat combined TS and mitral stenosis, as well as in cases of combined tricuspid, aortic, and mitral stenosis [<a href="#rid45">45,53,54</a>].</p><p>Complications for tricuspid balloon valvotomy include new or worsened tricuspid regurgitation (generally mild in published reports), bleeding, and access site complications.</p><p>Limited data are available on long-term outcomes. A report of four patients with severe TS who were successfully treated with balloon valvotomy found that symptomatic and hemodynamic improvements persisted at three-year follow-up [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H113764357"><span class="h3">Surgical valve replacement or repair</span><span class="headingEndMark"> — </span>Among patients with TS undergoing tricuspid valve surgery, most patients require tricuspid valve replacement given the extent of valvular and subvalvular disease. Surgical tricuspid valve repair is attempted if feasible (eg, with just one or two fused commissures), but valve replacement is performed if repair is not adequate.</p><p>Limited data are available comparing surgical tricuspid repair and surgical tricuspid valve replacement in patients with TS:</p><p class="bulletIndent1"><span class="glyph">●</span>Hospital mortality is higher in patients undergoing tricuspid valve replacement compared with those undergoing repair (for tricuspid regurgitation and/or TS), but at least part of this difference may be due to differences in risk factors. In a study of 28,726 admissions for tricuspid valve surgery during 1999 to 2008, hospital mortality for tricuspid valve replacement was higher than for tricuspid valve repair (13.6 versus 9.5 percent) [<a href="#rid48">48</a>]. However, the difference in mortality between the replacement and repair groups was no longer significant in the subset of patients with liver disease undergoing tricuspid valve surgery. Mortality for replacement remained higher than for repair in the subset of patients without liver disease. Further risk adjustment was not performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term mortality rates may be similar. A report of a series of 530 patients undergoing tricuspid valve surgery (for tricuspid regurgitation and/or TS) from 1961 to 1987 found no difference in survival rates or reoperation rates following tricuspid valve repair versus replacement at median four-year follow-up [<a href="#rid56">56</a>].</p><p></p><p class="headingAnchor" id="H113764364"><span class="h3">Choice of prosthesis in patients requiring valve replacement</span><span class="headingEndMark"> — </span>For patients requiring tricuspid valve replacement for TS, a bioprosthetic or mechanical valve may be chosen, and evidence to guide valve choice is limited. Considerations are similar to those for choice of a prosthetic valve generally (based largely on mitral and aortic data), but data specific to tricuspid valve replacement are limited [<a href="#rid57">57</a>]. As for prosthetic valves in any position, for patients with limited life expectancy, the increased ongoing risk of anticoagulation to avoid thrombotic complications with a mechanical valve may outweigh the long-term risk of valve failure due to structural valve degeneration with a bioprosthetic valve. (See  <a class="medical medical_review" href="/d/html/8143.html" rel="external">"Choice of prosthetic heart valve for surgical aortic or mitral valve replacement"</a>.)</p><p>Available data suggest no survival difference based upon prosthetic type for tricuspid valve replacement (combining TS and tricuspid regurgitation cases). A systematic review reported a pooled survival hazard ratio for mechanical versus bioprosthetic tricuspid valve of 1.07 (95% CI 0.84-1.35) [<a href="#rid49">49</a>]. The pooled freedom from reoperation hazard ratio was 1.24 (95% CI 0.64-2.31).</p><p>For valve replacement for TS, the 2014 AHA/ACC valve guideline noted only that the choice of prosthesis should be individualized [<a href="#rid32">32</a>]. The 2012 ESC valve guidelines indicate that a bioprosthesis is usually preferred over a mechanical prosthesis in this setting due to concern of higher risk of thrombosis with mechanical valves and satisfactory durability of tricuspid bioprosthetic valves but acknowledge that this is still a matter of debate [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H11"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>Management of pregnancy in patients with TS is discussed separately. (See  <a class="medical medical_review" href="/d/html/97124.html" rel="external">"Pregnancy and valve disease", section on 'Tricuspid stenosis'</a>.)</p><p class="headingAnchor" id="H4179980438"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H23216922"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient education” and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83897.html" rel="external">"Patient education: Tricuspid stenosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Tricuspid stenosis (TS) is most commonly of rheumatic etiology. Rheumatic TS almost never occurs as an isolated lesion; it is often accompanied by tricuspid regurgitation and is generally associated with mitral valve disease and, in some cases, aortic valve disease. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with TS, obstruction to tricuspid flow limits cardiac output, causes fatigue, and produces symptoms and signs of systemic venous hypertension. Concomitant mitral or aortic disease may cause additional symptoms such as dyspnea. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TS should be suspected in patients with signs and symptoms of systemic venous hypertension, particularly those with conditions associated with TS. TS is generally diagnosed and evaluated by transthoracic echocardiogram. (See <a class="local">'Approach to diagnosis and evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography is the most important modality utilized to identify TS. Severe TS is identified by the characteristic abnormal morphology on two-dimensional imaging accompanied by Doppler identification of a pressure half-time ≥190 ms and valve area ≤1 cm<sup>2</sup>. Stage C is defined as severe TS without symptoms. Stage D is defined as severe TS with symptoms. (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since TS is a mechanical disorder, it is most effectively treated by valve intervention, ie, valve surgery (valve repair or replacement) or percutaneous balloon valvotomy. Medical management with diuretic therapy may help reduce symptoms of congestion and thus may be helpful prior to intervention as well as in patients who are not candidates for intervention. (See <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tricuspid valve intervention for TS (ie, valve surgery [valve repair or replacement] or percutaneous balloon valvotomy) is generally reserved for symptomatic patients with severe TS. (See <a class="local">'Indications for intervention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with isolated symptomatic severe TS with low to moderate surgical risk, we suggest tricuspid valve surgery rather than balloon valvotomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with isolated symptomatic severe TS and mild or less tricuspid regurgitation with high surgical risk, we suggest balloon valvotomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Tumor masses, vegetations, and thrombi are contraindications to valvotomy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with isolated symptomatic severe TS and moderate or greater tricuspid regurgitation with high surgical risk, we perform an individualized assessment of the risks and benefits of tricuspid valve surgery versus medical therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with severe TS requiring surgery for left-sided valve disease, we suggest concomitant tricuspid valve surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Indications for intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients undergoing tricuspid valve surgery for TS generally require valve replacement, with surgical tricuspid valve repair attempted only when deemed feasible (eg, with just one or two fused commissures). (See <a class="local">'Surgical valve replacement or repair'</a> above.)</p><p></p><p class="headingAnchor" id="H3394219524"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William H Gaasch, MD (deceased), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Asmarats L, Taramasso M, Rodés-Cabau J. Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. Nat Rev Cardiol 2019; 16:538.</a></li><li><a class="nounderline abstract_t">Waller BF, Howard J, Fess S. Pathology of tricuspid valve stenosis and pure tricuspid regurgitation--Part I. Clin Cardiol 1995; 18:97.</a></li><li><a class="nounderline abstract_t">Hauck AJ, Freeman DP, Ackermann DM, et al. Surgical pathology of the tricuspid valve: a study of 363 cases spanning 25 years. Mayo Clin Proc 1988; 63:851.</a></li><li><a class="nounderline abstract_t">Daniels SJ, Mintz GS, Kotler MN. Rheumatic tricuspid valve disease: two-dimensional echocardiographic, hemodynamic, and angiographic correlations. Am J Cardiol 1983; 51:492.</a></li><li><a class="nounderline abstract_t">Roguin A, Rinkevich D, Milo S, et al. Long-term follow-up of patients with severe rheumatic tricuspid stenosis. Am Heart J 1998; 136:103.</a></li><li><a class="nounderline abstract_t">Sharma S, Loya YS, Desai DM, Pinto RJ. Percutaneous double-valve balloon valvotomy for multivalve stenosis: immediate results and intermediate-term follow-up. Am Heart J 1997; 133:64.</a></li><li><a class="nounderline abstract_t">Yousof AM, Shafei MZ, Endrys G, et al. Tricuspid stenosis and regurgitation in rheumatic heart disease: a prospective cardiac catheterization study in 525 patients. Am Heart J 1985; 110:60.</a></li><li><a class="nounderline abstract_t">Thatipelli MR, Uber PA, Mehra MR. Isolated tricuspid stenosis and heart failure: a focus on carcinoid heart disease. Congest Heart Fail 2003; 9:294.</a></li><li><a class="nounderline abstract_t">Ferreira S, Barbosa A, Gomes F, et al. An Unusual Case of Tricuspid Stenosis. Eur J Case Rep Intern Med 2018; 5:000836.</a></li><li><a class="nounderline abstract_t">Mocumbi AO. Right ventricular endomyocardial fibrosis (2013 Grover Conference series). Pulm Circ 2014; 4:363.</a></li><li><a class="nounderline abstract_t">Saito T, Horimi H, Hasegawa T, Kamoshida T. Isolated tricuspid valve stenosis caused by infective endocarditis in an adult: report of a case. Surg Today 1993; 23:1081.</a></li><li><a class="nounderline abstract_t">Gur AK, Odabasi D, Kunt AG, Kunt AS. Isolated tricuspid valve repair for Libman-Sacks endocarditis. Echocardiography 2014; 31:E166.</a></li><li><a class="nounderline abstract_t">Weidemann F, Strotmann JM, Niemann M, et al. Heart valve involvement in Fabry cardiomyopathy. Ultrasound Med Biol 2009; 35:730.</a></li><li><a class="nounderline abstract_t">Randhawa VK, Vakamudi S, Phelan DM, et al. Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition. ESC Heart Fail 2020; 7:1130.</a></li><li><a class="nounderline abstract_t">Nisanci Y, Yilmaz E, Oncul A, Ozsaruhan O. Predominant tricuspid stenosis secondary to bacterial endocarditis in a patient with permanent pacemaker and balloon dilatation of the stenosis. Pacing Clin Electrophysiol 1999; 22:393.</a></li><li><a class="nounderline abstract_t">Unger P, Clevenbergh P, Crasset V, et al. Pacemaker-related endocarditis inducing tricuspid stenosis. Am Heart J 1997; 133:605.</a></li><li><a class="nounderline abstract_t">Hagers Y, Koole M, Schoors D, Van Camp G. Tricuspid stenosis: a rare complication of pacemaker-related endocarditis. J Am Soc Echocardiogr 2000; 13:66.</a></li><li><a class="nounderline abstract_t">Essandoh M, Zuleta-Alarcon A, Weiss R, et al. Transesophageal echocardiographic diagnosis of severe functional tricuspid stenosis during infected implantable cardioverter-defibrillator lead extraction. J Cardiothorac Vasc Anesth 2015; 29:412.</a></li><li><a class="nounderline abstract_t">Rosenberg Y, Myatt JP, Feldman M, et al. Down to the wire: tricuspid stenosis in the setting of multiple pacing leads. Pacing Clin Electrophysiol 2010; 33:e49.</a></li><li><a class="nounderline abstract_t">Heaven DJ, Henein MY, Sutton R. Pacemaker lead related tricuspid stenosis: a report of two cases. Heart 2000; 83:351.</a></li><li><a class="nounderline abstract_t">Cevasco M, Shekar PS. Surgical management of tricuspid stenosis. Ann Cardiothorac Surg 2017; 6:275.</a></li><li><a class="nounderline abstract_t">Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 1997; 18:701.</a></li><li><a class="nounderline abstract_t">Munirathinam GK, Kumar B, Mishra AK. Tricuspid stenosis: A rare and potential complication of ventricular septal occluder device. Ann Card Anaesth 2018; 21:195.</a></li><li><a class="nounderline abstract_t">Cohen ML, Spray T, Gutierrez F, et al. Congenital tricuspid valve stenosis with atrial septal defect and left anterior fascicular block. Clin Cardiol 1990; 13:497.</a></li><li><a class="nounderline abstract_t">Fasoli G, Scognamiglio R, Daliento L. Uncommon pattern of tricuspid stenosis in Ebstein's anomaly. Int J Cardiol 1985; 9:488.</a></li><li><a class="nounderline abstract_t">Reddy G, Ahmed M, Alli O. Percutaneous valvuloplasty for severe bioprosthetic tricuspid valve stenosis in the setting of infective endocarditis. Catheter Cardiovasc Interv 2015; 85:925.</a></li><li><a class="nounderline abstract_t">Lilly SM, Rome J, Anwaruddin S, et al. How should I treat prosthetic tricuspid stenosis in an extreme surgical risk patient? EuroIntervention 2013; 9:407.</a></li><li><a class="nounderline abstract_t">Mao M, Madhavan M, Blauwet L, et al. Bioprosthetic tricuspid valve stenosis in end-stage renal failure. Am J Med Sci 2012; 343:252.</a></li><li><a class="nounderline abstract_t">Yamazaki Y, Wada T, Kadohama T, et al. Pacemaker Lead-induced Tricuspid Valve Stenosis and Reverse Lutembacher Syndrome. Ann Thorac Surg 2022; 114:e113.</a></li><li><a class="nounderline abstract_t">Fisher J. Jugular venous valves and physical signs. Chest 1984; 85:685.</a></li><li><a class="nounderline abstract_t">Morgan JR, Forker AD, Coates JR, Myers WS. Isolated tricuspid stenosis. Circulation 1971; 44:729.</a></li><li><a class="nounderline abstract_t">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57.</a></li><li><a class="nounderline abstract_t">Pérez JE, Ludbrook PA, Ahumada GG. Usefulness of Doppler echocardiography in detecting tricuspid valve stenosis. Am J Cardiol 1985; 55:601.</a></li><li><a class="nounderline abstract_t">Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22:1.</a></li><li><a class="nounderline abstract_t">Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.</a></li><li><a class="nounderline abstract_t">Paulus BM, Ali S, Zia AA, et al. Causes and consequences of systemic venous hypertension. Am J Med Sci 2008; 336:489.</a></li><li><a class="nounderline abstract_t">Rama-Merchan JC, Arribas-Jimenez A, Martin-Moreiras J, et al. Pacemaker lead-related tricuspid stenosis successfully treated with percutaneous balloon valvuloplasty guided by 3D echocardiography. Rev Port Cardiol 2014; 33:739.e1.</a></li><li><a class="nounderline abstract_t">Michiels V, Delabays A, Eeckhout E. Percutaneous balloon valvotomy for the treatment of pacemaker lead-induced tricuspid stenosis. Heart 2014; 100:352.</a></li><li><a class="nounderline abstract_t">Hussain T, Knight WB, McLeod KA. Lead-induced tricuspid stenosis--successful management by balloon angioplasty. Pacing Clin Electrophysiol 2009; 32:140.</a></li><li><a class="nounderline abstract_t">Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451.</a></li><li><a class="nounderline abstract_t">Adler DS. Non-functional tricuspid valve disease. Ann Cardiothorac Surg 2017; 6:204.</a></li><li><a class="nounderline abstract_t">Seghatol FF, Rigolin VH. Appetite suppressants and valvular heart disease. Curr Opin Cardiol 2002; 17:486.</a></li><li><a class="nounderline abstract_t">Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38:2739.</a></li><li><a class="nounderline abstract_t">Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017.</a></li><li><a class="nounderline abstract_t">Sancaktar O, Kumbasar SD, Semiz E, Yalçinkaya S. Late results of combined percutaneous balloon valvuloplasty of mitral and tricuspid valves. Cathet Cardiovasc Diagn 1998; 45:246.</a></li><li><a class="nounderline abstract_t">Yeter E, Ozlem K, Kiliç H, et al. Tricuspid balloon valvuloplasty to treat tricuspid stenosis. J Heart Valve Dis 2010; 19:159.</a></li><li><a class="nounderline abstract_t">Lee R, Li S, Rankin JS, et al. Fifteen-year outcome trends for valve surgery in North America. Ann Thorac Surg 2011; 91:677.</a></li><li><a class="nounderline abstract_t">Vassileva CM, Shabosky J, Boley T, et al. Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database. J Thorac Cardiovasc Surg 2012; 143:1043.</a></li><li><a class="nounderline abstract_t">Rizzoli G, Vendramin I, Nesseris G, et al. Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg 2004; 77:1607.</a></li><li><a class="nounderline abstract_t">Ribeiro PA, Al Zaibag M, Al Kasab S, et al. Percutaneous double balloon valvotomy for rheumatic tricuspid stenosis. Am J Cardiol 1988; 61:660.</a></li><li><a class="nounderline abstract_t">Orbe LC, Sobrino N, Arcas R, et al. Initial outcome of percutaneous balloon valvuloplasty in rheumatic tricuspid valve stenosis. Am J Cardiol 1993; 71:353.</a></li><li><a class="nounderline abstract_t">Patel TM, Dani SI, Shah SC, Patel TK. Tricuspid balloon valvuloplasty: a more simplified approach using inoue balloon. Cathet Cardiovasc Diagn 1996; 37:86.</a></li><li><a class="nounderline abstract_t">Ashraf T, Pathan A, Kundi A. Percutaneous balloon valvuloplasty of coexisting mitral and tricuspid stenosis: single-wire, double-balloon technique. J Invasive Cardiol 2008; 20:E126.</a></li><li><a class="nounderline abstract_t">Sobrino N, Calvo Orbe L, Merino JL, et al. Percutaneous balloon valvuloplasty for concurrent mitral, aortic and tricuspid rheumatic stenosis. Eur Heart J 1995; 16:711.</a></li><li><a class="nounderline abstract_t">Ribeiro PA, al Zaibag M, Idris MT. Percutaneous double balloon tricuspid valvotomy for severe tricuspid stenosis: 3-year follow-up study. Eur Heart J 1990; 11:1109.</a></li><li><a class="nounderline abstract_t">McGrath LB, Gonzalez-Lavin L, Bailey BM, et al. Tricuspid valve operations in 530 patients. Twenty-five-year assessment of early and late phase events. J Thorac Cardiovasc Surg 1990; 99:124.</a></li><li><a class="nounderline abstract_t">Kunadian B, Vijayalakshmi K, Balasubramanian S, Dunning J. Should the tricuspid valve be replaced with a mechanical or biological valve? Interact Cardiovasc Thorac Surg 2007; 6:551.</a></li></ol></div><div id="topicVersionRevision">Topic 8136 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30988448" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7720297" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pathology of tricuspid valve stenosis and pure tricuspid regurgitation--Part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3045434" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgical pathology of the tricuspid valve: a study of 363 cases spanning 25 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823865" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rheumatic tricuspid valve disease: two-dimensional echocardiographic, hemodynamic, and angiographic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9665226" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term follow-up of patients with severe rheumatic tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006292" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Percutaneous double-valve balloon valvotomy for multivalve stenosis: immediate results and intermediate-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4013991" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tricuspid stenosis and regurgitation in rheumatic heart disease: a prospective cardiac catheterization study in 525 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564150" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Isolated tricuspid stenosis and heart failure: a focus on carcinoid heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30756028" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : An Unusual Case of Tricuspid Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25621149" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Right ventricular endomyocardial fibrosis (2013 Grover Conference series).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8118123" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Isolated tricuspid valve stenosis caused by infective endocarditis in an adult: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24661289" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Isolated tricuspid valve repair for Libman-Sacks endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19110366" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Heart valve involvement in Fabry cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32175673" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10087561" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Predominant tricuspid stenosis secondary to bacterial endocarditis in a patient with permanent pacemaker and balloon dilatation of the stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141386" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pacemaker-related endocarditis inducing tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10625835" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tricuspid stenosis: a rare complication of pacemaker-related endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440647" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transesophageal echocardiographic diagnosis of severe functional tricuspid stenosis during infected implantable cardioverter-defibrillator lead extraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20070545" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Down to the wire: tricuspid stenosis in the setting of multiple pacing leads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10677419" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pacemaker lead related tricuspid stenosis: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28706872" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Surgical management of tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129909" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29652285" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tricuspid stenosis: A rare and potential complication of ventricular septal occluder device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2364584" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Congenital tricuspid valve stenosis with atrial septal defect and left anterior fascicular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4077306" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Uncommon pattern of tricuspid stenosis in Ebstein's anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399759" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Percutaneous valvuloplasty for severe bioprosthetic tricuspid valve stenosis in the setting of infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23872655" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : How should I treat prosthetic tricuspid stenosis in an extreme surgical risk patient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22104429" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bioprosthetic tricuspid valve stenosis in end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34921816" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pacemaker Lead-induced Tricuspid Valve Stenosis and Reverse Lutembacher Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6713978" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Jugular venous valves and physical signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5094152" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Isolated tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603191" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969915" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Usefulness of Doppler echocardiography in detecting tricuspid valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19130998" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18820172" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092322" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Causes and consequences of systemic venous hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455950" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pacemaker lead-related tricuspid stenosis successfully treated with percutaneous balloon valvuloplasty guided by 3D echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24052372" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Percutaneous balloon valvotomy for the treatment of pacemaker lead-induced tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19140926" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lead-induced tricuspid stenosis--successful management by balloon angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922415" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Guidelines on the management of valvular heart disease (version 2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28706863" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Non-functional tricuspid valve disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12357124" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Appetite suppressants and valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886619" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : 2017 ESC/EACTS Guidelines for the management of valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28298458" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9829880" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Late results of combined percutaneous balloon valvuloplasty of mitral and tricuspid valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20329507" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tricuspid balloon valvuloplasty to treat tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21352979" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fifteen-year outcome trends for valve surgery in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21872283" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111151" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3344697" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Percutaneous double balloon valvotomy for rheumatic tricuspid stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8427185" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Initial outcome of percutaneous balloon valvuloplasty in rheumatic tricuspid valve stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8770490" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Tricuspid balloon valvuloplasty: a more simplified approach using inoue balloon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18398244" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Percutaneous balloon valvuloplasty of coexisting mitral and tricuspid stenosis: single-wire, double-balloon technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7588907" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Percutaneous balloon valvuloplasty for concurrent mitral, aortic and tricuspid rheumatic stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2292258" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Percutaneous double balloon tricuspid valvotomy for severe tricuspid stenosis: 3-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2294345" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tricuspid valve operations in 530 patients. Twenty-five-year assessment of early and late phase events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17669933" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Should the tricuspid valve be replaced with a mechanical or biological valve?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
